Last reviewed · How we verify
AZD1722 and Midazolam
At a glance
| Generic name | AZD1722 and Midazolam |
|---|---|
| Sponsor | Ardelyx |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD1722 and Midazolam CI brief — competitive landscape report
- AZD1722 and Midazolam updates RSS · CI watch RSS
- Ardelyx portfolio CI